[go: up one dir, main page]

MXPA05013016A - Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos. - Google Patents

Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.

Info

Publication number
MXPA05013016A
MXPA05013016A MXPA05013016A MXPA05013016A MXPA05013016A MX PA05013016 A MXPA05013016 A MX PA05013016A MX PA05013016 A MXPA05013016 A MX PA05013016A MX PA05013016 A MXPA05013016 A MX PA05013016A MX PA05013016 A MXPA05013016 A MX PA05013016A
Authority
MX
Mexico
Prior art keywords
treating depression
aboxadol
affective disorders
gaboxadol
pharmaceutical composition
Prior art date
Application number
MXPA05013016A
Other languages
English (en)
Inventor
Connie Sanchez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MXPA05013016A publication Critical patent/MXPA05013016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invencion se relaciona con el uso de gaboxadol en la preparacion de una composicion farmaceutica para el tratamiento de la depresion. Ademas, se relaciona con el uso de gaboxadol en la preparacion de una composicion farmaceutica para ser utilizada en combinacion con un inhibidor de la reabsorcion de serotonina o cualquier otro compuesto que logra una elevacion en el nivel de serotonina extracelular.
MXPA05013016A 2003-06-25 2004-06-25 Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos. MXPA05013016A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48301903P 2003-06-25 2003-06-25
DKPA200300956 2003-06-25
US53512304P 2004-01-07 2004-01-07
DKPA200400016 2004-01-07
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
MXPA05013016A true MXPA05013016A (es) 2006-03-02

Family

ID=33545397

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013016A MXPA05013016A (es) 2003-06-25 2004-06-25 Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.

Country Status (17)

Country Link
EP (2) EP2145620A3 (es)
JP (1) JP2007508236A (es)
AT (1) ATE459353T1 (es)
AU (1) AU2004248890A1 (es)
BR (1) BRPI0410857A (es)
CY (1) CY1110046T1 (es)
DE (1) DE602004025808D1 (es)
DK (1) DK1641456T3 (es)
ES (1) ES2341004T3 (es)
HR (1) HRP20100276T1 (es)
IL (2) IL172631A0 (es)
MX (1) MXPA05013016A (es)
NZ (1) NZ543586A (es)
PL (1) PL1641456T3 (es)
PT (1) PT1641456E (es)
SI (1) SI1641456T1 (es)
WO (1) WO2004112786A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663218A1 (en) * 2003-09-10 2006-06-07 MERCK SHARP &amp; DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
EP2343073A3 (en) 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1742624B1 (en) 2004-02-18 2010-01-06 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1906953A4 (en) * 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL
TW200920358A (en) * 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2732636A1 (en) * 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
US10626123B2 (en) 2015-03-24 2020-04-21 H. Lundbeck A/S Manufacture of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
AU2019249277A1 (en) * 2018-04-06 2020-10-22 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of substance use disorders
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
SG11202105349XA (en) * 2018-11-21 2021-06-29 Certego Therapeutics Combination of gaboxadol and lithium for the treatment of psychiatric disorders
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
CZ20033269A3 (en) 2001-05-21 2004-03-17 H. Lundbeck A/S Granular preparations of gaboxadol

Also Published As

Publication number Publication date
AU2004248890A1 (en) 2004-12-29
WO2004112786A3 (en) 2005-04-14
PL1641456T3 (pl) 2010-08-31
EP1641456A2 (en) 2006-04-05
HRP20100276T1 (hr) 2010-06-30
IL202106A0 (en) 2010-06-16
JP2007508236A (ja) 2007-04-05
EP2145620A3 (en) 2010-03-17
SI1641456T1 (sl) 2010-06-30
EP2145620A2 (en) 2010-01-20
DK1641456T3 (da) 2010-06-21
IL172631A0 (en) 2006-04-10
WO2004112786A2 (en) 2004-12-29
DE602004025808D1 (de) 2010-04-15
NZ543586A (en) 2009-07-31
EP1641456B1 (en) 2010-03-03
ATE459353T1 (de) 2010-03-15
CY1110046T1 (el) 2015-01-14
PT1641456E (pt) 2010-06-01
ES2341004T3 (es) 2010-06-14
BRPI0410857A (pt) 2006-07-04

Similar Documents

Publication Publication Date Title
IL202106A0 (en) Gaboxadol for treating depression and other affective disorders
TW201713640A (en) Bruton&#39;s tyrosine kinase inhibitors
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
TW200740799A (en) Alpha2C adrenoreceptor agonists
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
MX359668B (es) Derivados de retinal y metodos para su uso en el tratamiento de trastornos visuales.
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX368459B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
TW200745122A (en) New compounds I
TW200736227A (en) New compounds III
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2009013126A (es) Nuevos compuestos 892.
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.
UA95907C2 (en) Mitotic kinesin inhibitors and methods of use thereof
UA90656C2 (ru) Габоксадол для лечения депрессии
MEP1908A (xx) Gabaksadol za liječenje depresije i drugih afektivnih poremećaja
WO2007121883A3 (de) 1,4:3,6-dianhydromannitol-derivate und deren verwendung
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
WO2009105218A3 (en) Propiophenone derivatives
MX2010004422A (es) Compuestos de 2,3-dihidro-benzofurano.
CL2009001113A1 (es) Compuestos derivados de 4,5-diarilpirrol-2-carboxamida; procedimiento de preparacion de estos; composicion farmaceutica que los comprende; uso en el tratamiento y/o prevencion de trastornos psiquiatricos, dependencia a sustancias, entre otras.

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general